ArticleResearch square2026
EMT activates ER-to-Golgi trafficking through upregulation of REEP2 to promote lung cancer progression.
Kevin Fulp, Oluwafunminiyi Obaleye, Shike Wang, Xin Liu, Jiang Yu, Jonathan M Kurie, Jun Xu, William K Russell, Xiaochao Tan, Guan-Yu Xiao
Abstract readPreprint
In one paragraphArticle in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Kevin FulpDepartment of Toxicology and Cancer Biology, The University of Kentucky College of Medicine, Lexington, Kentucky.
Oluwafunminiyi ObaleyeDepartment of Toxicology and Cancer Biology, The University of Kentucky College of Medicine, Lexington, Kentucky.
Shike WangDepartment of Medicine, Tulane University School of Medicine, Louisiana Cancer Research Center, New Orleans, Louisiana.
Xin LiuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jiang YuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jonathan M KurieDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1472-8719 Jun XuDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas.
William K RussellDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas.ORCID 0000-0003-1931-4555 Xiaochao TanDepartment of Medicine, Tulane University School of Medicine, Louisiana Cancer Research Center, New Orleans, Louisiana.ORCID 0000-0002-8603-5700 Guan-Yu XiaoDepartment of Toxicology and Cancer Biology, The University of Kentucky College of Medicine, Lexington, Kentucky.ORCID 0000-0003-3454-6717 Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4MUniversity of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3MRegulation of lung cancer metastasis through transcriptional control of the Golgi apparatusR01CA211125 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2017 to 2021
$1.8MRegulation of Lung Cancer Metastasis by ZEB1R01CA181184 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2014 to 2018
$1.7MA pro-metastatic secretory program activated by epithelial-to-mesenchymal transitionR00CA249048 · NCI · UNIVERSITY OF KENTUCKY · PI GUAN-YU XIAO · 2024 to 2026
$747kAn actionable secretory program that drives tumor progression in a genetically defined subset of lung squamous carcinomaR03CA280382 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TAN, XIAOCHAO · 2023 to 2024
$158kNCI NIH HHS P30 CA177558NCI NIH HHS P50 CA070907NCI NIH HHS R00 CA249048NCI NIH HHS R01 CA181184NCI NIH HHS R01 CA211125NCI NIH HHS R03 CA280382
6 · The paper itselfAbstract
Membrane trafficking governs the transport of molecules to both intracellular and extracellular locations, thereby maintaining cell homeostasis. During cancer progression, alterations in membrane trafficking are frequently observed. However, the mechanisms underlying the dysregulation of membrane trafficking in cancer progression remain largely unresolved. Recent evidence has demonstrated that epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma (LUAD) employs a membrane trafficking program to coordinate cancer cell invasion and immunosuppression in the tumor microenvironment (TME). To further dissect the pro-tumorigenic membrane trafficking program, here we conducted a CRISPR interference (CRISPRi)
Identifiers
PMID42539061
PMCPMC13419587
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390